EUCTR2011-001711-31-IT进行中（未招募）不适用
A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia - PEARL Mainteinance
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Screening and Open-label Stabilization Phase 1 Subject is = 18 and = 75 years of age, on the day of signing the informed consent. 2. Subject meets DSM-IV-TR criteria for a primary diagnosis of schizophrenia [including disorganized (295.10), paranoid (295.30), undifferentiated (295.90) subtypes as established by clinical interview (using the DSM-IV-TR as a reference and confirmed using the SCID-CT)]. The duration of the subject`s illness whether treated or untreated must be = 1 year. 3. Subject has had at least one prior episode of psychotic exacerbation as judged by the Investigator in the two years preceding screening. 4. Subject has a PANSS Total score = 80 with a score = 4 on 1 or more of any PANSS Positive subscale items at screening and open-label baseline (Visit 2). 5. Subject has a CGI-S score of = 4 at screening and open-label baseline (Visit 2). Double-blind Phase 1. a PANSS Total score = 70, a CGI-S score < 4 and a PANSS item score of =4 (moderate or less)on all PANSS Positive subscale items over at least 12 weeks with the allowance of two excursions (except during the last 4 weeks of the open-label phase) assessed at weekly study visits: • An excursion is defined as a PANSS total score up to a maximum of 80 and/or CGI-S score up to a maximum of 4 and/or a PANSS Positive subscale item score up to a maximum of 5. 2. a PANSS item score of = 4 (moderate or less) on all item G8 (uncooperativeness) 3. taking a stable dose of lurasidone for the last 4 weeks of the openlabel phase.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1098
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 122
排除标准
- •Screening and Open-label Stabilization Phase 1. Subject has a DSM-IV Axis I or Axis II diagnosis other than schizophrenia that has been the primary focus of treatment within 3 months of screening. 2. Subject answers `yes` to `Suicidal Ideation` item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at screening (in the past month)or baseline. 3. Subject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation. 4. Subject with Type 1 or Type 2 insulin-dependent diabetes. 5. Subject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator. 6. Subject has a prolactin concentration > 100 ng/mL at screening or has a history of pituitary adenoma. 7. Subject is judged to be resistant to antipsychotic treatment defined as any one of the following: a. failure to respond to > 2 marketed antipsychotic agents, given at an adequate dose and for an adequate duration (within the past 2 years) b. history of treatment with clozapine for refractory psychosis Double-blind Phase 1. Subject who in the Investigator`s judgment have been non-compliant with study medication and/or study assessments during the open-label stabilization phase.
研究者
相似试验
招募中
3 期
A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome2024-517155-13-00IRCCS Istituto Giannina Gaslini24
进行中（未招募）
1 期
A Phase 2 study to evaluate the Safety and Efficacy of CRN00808 for the treatment of acromegalyAcromegalyMedDRA version: 20.0Level: PTClassification code 10000599Term: AcromegalySystem Organ Class: 10014698 - Endocrine disordersEUCTR2018-001833-42-HUCrinetics Pharmaceuticals, Inc.40
进行中（未招募）
1 期
A Phase 2 study to evaluate the Safety and Efficacy of CRN00808 for the treatment of acromegalyMedDRA version: 20.0Level: PTClassification code 10000599Term: AcromegalySystem Organ Class: 10014698 - Endocrine disordersAcromegalyEUCTR2018-001833-42-GRCrinetics Pharmaceuticals, Inc.40
进行中（未招募）
1 期
A Phase 2 study to evaluate the Safety and Efficacy of CRN00808 for the treatment of acromegalyAcromegalyEUCTR2018-001833-42-GBCrinetics Pharmaceuticals, Inc.40
进行中（未招募）
1 期
A Phase 2 study to evaluate the Safety and Efficacy of CRN00808 for the treatment of acromegalyAcromegalyEUCTR2018-001833-42-ITCrinetics Pharmaceuticals, Inc.40